U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
MORRISTOWN, N.J., May 08, 2017 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) a specialty pharmaceutical company, announced today that the Company will report financial results for the first quarter ended March 31, 2017, after the market close on Monday, May 15, 2017. John Sedor, Chairman and Chief Executive Officer, and Graham Miao, President and Chief Financial Officer, will host a conference call to discuss the results.
| Date: | Monday, May 15 | ||
| Time: | 4:30 PM ET | ||
| Toll free (U.S.): | 888-504-7953 | ||
| International: | 719-457-2643 | ||
| Conference ID: | 4336660 | ||
| Webcast: | http://public.viavid.com/index.php?id=124373 |
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force, uses contracted sales organizations to market its non-core, cough and cold products, and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT Investor Relations Matthew P. Duffy, 212-915-0685 LifeSci Advisors, LLC [email protected]
